The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Blahblah, hopefully we will know soon. One piece of feed back from a poster here that attended the presentation was the lab/quarantine facility has gone from 30% utilised in 2019 to an expected 100% utilisation for 2020, I am personally happy with that on its own.
OK Shandy, but the viral lab on its own, after removing all the careful qualifiers, is not unique, so it's value is less than the messaging suggests. Not sure what can be done here that hasn't already been done in Wuhan or the US, or any number of other labs? Also, the outbreak in China may have originated in animals, but surely only the initial jump? It doesn't make sense that "human to human" contagion is somehow less dangerous, since all of it apart from the original jump will have been human to human? The WHO are not reporting any difference in the mortality rates inside and outside China, AFAIK.
Shandypants2
Spot on.
Blah - it is the viral lab not the quarantine facility that is relevant for corona. The challenge study is for existing viruses that HVO 'own'.
It may get used, it may not. Cathal suggested that Prof Oxford would be able to potentially get access to the virus and undertake tests on it. Clearly all speculation at this point.
Also Corona has focused minds on other viruses which is where HVO should add value - e.g flu jab etc
Europe's only 24 bedroom quarantine clinic with onsite virology lab. Yes but the clinic does not have a model for coronavirus, so how does it perform challenge tests without a model? Anyone who has a coronavirus model presumably has their own lab (albeit not in Europe, or perhaps just not with an onsite lab)? You seem to be suggesting there are coronavirus model owners without labs who may be adapting ORPH's facilities, or perhaps doing something other than challenge tests?
This for a start:
Europe's only 24 bedroom quarantine clinic with onsite virology lab in Queen Mary's Hospital London
None of the vaunted ORPH 'challenge study models' are for coronavirus, so even if/when a vaccine is developed the existing models don't seem to give ORPH relevance? Struggling to understand exactly what they have to offer wrt covid19, it all seems rather vague considering we have a world expert advising.
Should see a big breakout now, seller finished imo
hVIVO supports product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of the Coronavirus in 2020. The company also has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models. No other company in the world has such a portfolio, with only two competitors globally having 1 challenge study model each.
Spotlight article
OpenOrphan lining up for Coronavirus fight
*Expand view in browser for max zoom.
Page 1:
https://novuscomms.com/wp-content/uploads/2020/02/SS_ORPH1-680x899.png
Page 2:
https://novuscomms.com/wp-content/uploads/2020/02/SS_ORPH2-680x893.png
Page 3:
https://novuscomms.com/wp-content/uploads/2020/02/SS_ORPH3-680x895.png